Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation Page 4 • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth • 17 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Steve Newlin Appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2013 2014 and beyond -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $38.38 March 7th, 2014 • 17 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 5 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% United States 66% Europe 14% Canada 7% Asia 6% Latin America 7% PP&S 20% Specialty 53% Distribution 27% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target Ad ju st ed E ar ni ng s P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 6 PolyOne At A Glance Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty Specialty OI $5M $46M $87M $195M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 2013 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.2% 12 – 16% Global Specialty Engineered Materials 1.1% 9.3% 12 – 16% Designed Structures & Solutions -- 5.6% 8 – 10% Performance Products & Solutions 5.4% 7.2% 9 – 12% Distribution 2.6% 5.9% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.1% 15% 4) Adjusted EPS Growth N/A 31% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 Bridge To $2.50 Adjusted EPS By 2015 2015 EPS: $2.50 2013 EPS: $1.31 Mid single digit revenue CAGR Page 9 Mergers & Acquisitions Spartech accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 10 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 43.0% 2006 2013 Healthcare Consumer Packaging and Additive Technology Transportation Page 11 Unique and Innovative Solutions that Help Customers Win https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG Net Debt / EBITDA* = 1.8x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Significant Debt Maturities As of December 31, 2013 ($ millions) Page 12 Coupon Rates: 7.500% 7.375% 5.250% Debt Maturities & Pension Funding – 12/31/13 *TTM 12/31/2013 ** includes US-qualified plans only 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2013 Pension Funding** As of December 31, 2013 Free Cash Flow and Strong Balance Sheet Fund Investment •Targets that expand our: • Specialty offerings •End market presence •Geographic footprint •Operating Margin • Synergy opportunities •Adjacent material solutions •Expanding our sales, marketing, and technical capabilities • Investing in operational and LSS initiatives (including synergy capture) •Manufacturing alignment Organic Growth Share Repurchases Dividends Acquisitions Page 13 $0.16 $0.20 $0.24 $0.32 $0.00 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend • Repurchased ~5 million shares in 2013 • 15 million shares are available for repurchase under the current authorization The New PolyOne: A Specialty Growth Company 2015 Target: $2.50 Adjusted EPS Why Invest In PolyOne? Strong past performance demonstrates that our strategy and execution are working • Megatrends align with our strengths • Innovation and services provide differentiation, incremental pricing power, and competitive advantage • Strong and proven management team driving growth and performance • Addressable market exceeds $40 billion Page 14 1 Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. Appendix At a Glance�Global Specialty Engineered Materials At a Glance�Global Color, Additives, and Inks At a Glance�Designed Structures and Solutions At a Glance�Performance Products and Solutions At a Glance�Distribution Plastics: Key to Future Sustainable Development Establish Lean Six Sigma As Way of Life Application Examples Slide Number 24 2012 Range Rover Evoque Interior Slide Number 26 Slide Number 27 Metal Replacement Solutions High-Barrier Packaging Containers Aerospace Applications Sidoti Reconciliation of Non-GAAP.pdf Section 1

Bir pozisyon için başvurduğunuz yerel Avient kuruluşunun yasal mercisi kişisel bilgileriniz konusunda veri denetleyicisi olarak hareket edecektir. 1. Bize Ulaşın Herhangi bir sorunuz varsa veya haklarınızı kullanmak isterseniz bize aşağıdaki adresten ulaşabilirsiniz: Kurumsal Gizlilik Yetkilisi Avient Corporation 33587 Walker Road Avon Lake, Ohio 44012 E-posta: PRIVACY.OFFICER@AVIENT.COM Telefon: 1-800-901-2078 mailto:PRIVACY.OFFICER@AVIENT.COM Gizlilik sorularınız veya taleplerinizi bize çevrimiçi formumuzu doldurarak da gönderebilirsiniz. Geçerlilik Tarihi: 1 Ağustos 2020 https://privacyportal.onetrust.com/webform/b25cf7b1-a93a-4d26-8c84-ceda4d0ae91b/e180cbe4-d1b9-49bd-b621-cb5f6a0f42cb mailto:PRIVACY.OFFICER@AVIENT.COM

ECert - 2024-03-22T104613.866.pdf Page 1 of 53 Validity of this certificate is based on the successful completion of the periodic surveillance audits of the management system defined by the above scope and is contingent upon prompt,written notification to ABS Quality Evaluations, Inc. of significant changes to the management system or components thereof. Dominic Townsend, President Effective Date: 22 March 2024 Expiration Date: 28 February 2025 Revision Date: 22 March 2024 Avient Corporation - Cota, Colombia Autopista Medellín Km 2.5, Via Parcelas Km 1 Vereda Siberia Cota, Cundinamarca 250017 Colombia Design and Manufacture of Colorants and Additives for Plastics 65536-116863Certificate No: Page 12 of 53 ABS Quality Evaluations ABS Quality Evaluations, Inc. 1701 City Plaza Drive, Spring, TX 77389, U.S.A. Dominic Townsend, President Effective Date: 22 March 2024 Expiration Date: 28 February 2025 Revision Date: 22 March 2024 Avient Pakistan (Private) Limited 1-A/1, Sector-20 Korangi Industrial Area Korangi, Sindh 74900 Pakistan Design and Manufacture of Colour and Additive Concentrates, Thermoplastic Resins and Specialty Compounds 65536-117317Certificate No: Page 20 of 53 ABS Quality Evaluations ABS Quality Evaluations, Inc. 1701 City Plaza Drive, Spring, TX 77389, U.S.A.

PMMA Considering lens performance, Resilience™ LS Frost PVC offers properties and material performance similar to PMMA, often at a significantly lower cost. 1 ASTM D-1003 measured by Polymer Diagnostics, Inc.

For and on behalf of BSI: Carlos Pitanga, Chief Operating Officer Assurance – Americas Certification Date: 2018-07-11 Latest Issue: 2018-07-11 Expiry Date: 2021-07-10 BSI Certificate Number: 85585 IATF Number: 0315491 Page: 1 of 2 This certificate remains the property of BSI and shall be returned immediately upon request.

MEVOPUR COLORANTS • Standard colors in PP and PE to shorten time-to-market • Custom colors matched to Pantone, RAL or other color reference • White colorants for pharmaceutical packaging for LDPE, HDPE and PP with opacity to reach USP chapter MEVOPUR FUNCTIONAL ADDITIVES • Antistatic formulation with good flow/impact for injection molding • Amide- and amine-free antistatic for film in contact with API (Active Pharmaceutical Ingredients) • UV blocking for transparent PP and PE packaging to meet USP chapter • Non-migrating friction reduction/processing aid for PE and PP • Laser marking/welding additive for fast, reliable marking/assembly • MVTR (Moisture Vapor Transmission Rate) reduction for HDPE to improve shelf-life • Thermal protection of the polymer during processing • Gamma/e-beam sterilization protection for PP (up to 50kGy) with color compensation for reduced yellowing REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Bormed™ is a registered trademark of Borealis Healthcare use limitations apply—see below.

REGULATORY SUPPORT • Drug delivery devices • Pharmaceutical packaging • Medical equipment KEY CHARACTERISTICS • Manufactured at four ISO 13485 certified sites, providing global consistency and increased security of supply • Documented change control beyond CAS number level, reducing the risk of change • Allows crystallization in semi-crystalline polymers to begin faster and complete earlier REGULATORY SUPPORT • Raw materials tested to: - ISO 10993-1 and USP biological evaluation - European Pharmacopeia 3.1.3/3.1.5 (polyolefin) - USP (polyethylene) - ICH Q3D elemental impurities • Registered Drug Master File (Type III) and/or Device Master File • Food contact established with FDA/EU* APPLICATION BULLETIN * FDA/EU compliance information available upon request Healthcare use limitations apply—see below.

According to the company, the precise thumb control and long-term comfort has made these new accessories “wildly popular.” 1 http://www.statista.com/statistics/237749/value-of-the-global- entertainment-and-media-market/ AVIENT HELPS GAMING ACCESSORIES COMPANY TAKE AIM AT NEW OPPORTUNITIES © 2020, All Rights Reserved Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012 To learn more, please contact Avient at +1.844.4AVIENT (1.844.428.4368)

The Avient team assessed the application’s technical and operational requirements, and recommended GLS Versalloy™ XL- 9045-1 alloy in 45 Shore A durometer, an FDA-compliant medical TPV grade designed for overmolding onto PP.

When slush molding a door panel, vinyl powder is added to a hot mold, which melts the powder to a 1 mm-thick coating, and the mold then rotates so that the melted material can fill the entire cavity.